Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie;Einsatz von biologika bei der juvenilen idiopathischen arthritis: Konsensus-statement des 7. Wörlitzer Expertengespräches 2004 für die Arbeitsgemeinschaft Kinder- und Jugendrheumatologie

Zeitschrift fur Rheumatologie

Volumn 65, Issue 2, 2006, Pages 152-158

  Horneff, G ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Adalimumab; Anakinra; Etanercept; Infliximab; Juvenile arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; GERMANY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL SOCIETY; REVIEW; TREATMENT INDICATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; GERMANY; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOLOGY; SOCIETIES, MEDICAL;

EID: 33645317398     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-005-0002-7     Document Type: Review

References (21)

1. Armbrust W, Kamphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W, Wulffraat NAM (2004) Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 43(4): 527-529
2. Banares A, Abasolo L, Maccaron P, Hernandez C, Jover JA, Fernandez B, Pato E (2001) Treatment of refractory posterior uveitis with anti-TNF-alpha (infliximab). Arthritis Rheum 44:90S
3. Billiau AD, Cornillie F, Wouters C (2002) Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol 29(5):1111-1114
4. Henrickson M (2004) Efficacy of Anakinra in Refractory Systemic Arthritis. 2004 Annual Scientific meeting of the American College of Rheumatology, October 16-21, San Antonio, USA
5. Horneff G, Biedermann T, Foeldvari I, Kuester RM, Moebius D, Michels H, Rogalski B, Schmeling H (2003) Combination therapy with methotrexate and etanercept compared to etanercept monotherapy. Clin Exp Rheumatol 21:540
6. Horneff G, Forster J, Seyberth H-W, Michels H, für die Arbeitsgemeinschaft Kinder- und Jugendrheumatologie (2001) Empfehlungen der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie zur Therapie mit Etanercept (P75 TNF-Rezeptor-Immunglobulinfusionsprotein). Z Rheumatol 59:365-369
7. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hosbach T, Huppertz HI, Keitzer R, Kuester RM, Michels H, Moebius D, Rogalski B, Thon A (2004) The German Etanercept Registry for Treatment of Juvenile Idiopathic Arthritis (JIA). Ann Rheum Dis 63:1638-1644
8. Ilowite NT, Porras O, Reiff A, Rudge SR, Punaro MG, Martin AL, Allen R, Harville TO, Kazazi F, Zhou L, Newmark R (2003) A twelve-week open label safety and efficacy study of anakinra (Kineret) in juvenile rheumatoid arthritis. Ann Rheum Dis 62:86S
9. Irigoyen PI, Olson J, Hom C, Ilowite NT (2004) Treatment of Systemic Onset Juvenile Rheumatoid Arthritis with Anakinra. Annual Scientific meeting of the American College of Rheumatology, October 16-21, San Antonio, USA
10. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ (2004) Once weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis. Results of a multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 50:353-363
11. Kimura Y, Imundo LF, Li SC (2001) High dose infliximab in the treatment of resistant systemic JRA. Arthritis Rheum 44:272S
12. Lahdenne P, Vahasalo P, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245-247
13. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763-769
14. Lovell DJ, Ruperto N, Goodman S, Reiff A, Martini A, Giannini EH, Radin AR, Rao VS, Spencer-Green G (2004) Preliminary Data from the Study of Adalimumab in Children with Juvenile Idiopathic Arthritis (JIA). Annual Scientific meeting of the American College of Rheumatology, October 16-21, San Antonio, USA
15. Manger B (2002) Überarbeitete Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie mit Tumornekrosefaktor- hemmenden Wirkstoffen bei entzündlich rheumatischen Erkrankungen (Stand Juli 2002). Z Rheumatol 61:694-697
16. Reiff A, Henrickson M (2001) Prolonged efficacy of etanercept in refractory juvenile ankylosing spondylitis. Arthritis Rheum 44:2925
17. Reiff A, Porras O, Rudge S, Punaro M, Allen R, Ilowite N, Martin AL, Lovell D, Kazazi F, Sun G, Newmark R (2002) Preliminary Data from a Study of Kineret (anakinra) in Children with Juvenile Rheumatoid Arthritis. Annual Scientific meeting of the American College of Rheumatology, October 25-29, New Orleans, USA
18. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44:1411-1415
19. Saadeh et al (2004) Successful treatment of Still's disease with anakinra after failure to respond to multiple therapeutic modalities including methotrexate, infliximab, immunoglobulins, etanercept and adalimumab. Ann Rheum Dis 63:81S
20. Schmeling H, Mathony K, John V, Keyßer G, Burdach St., Horneff G (2001) Combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis - a pilot study. Ann Rheum Dis 60:410-412
21. Tutar E, Ekici F, Nacar N, Arici S, Atalay S (2004) Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford), 43(5):674-675